Hypertension is a well-established major risk factor for cardiovascular diseases (CVD), often coexisting with metabolic disorders like type 2 diabetes mellitus (T2DM), compounding their cardiovascular risk [1]. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were originally developed as antidiabetic agents to improve glycemic control. Beyond glucose lowering, GLP-1 RAs have been shown to confer broad cardioprotective benefits including reductions in body weight, blood pressure, postprandial lipids, and inflammation [2]. These agents mimic the incretin hormone GLP-1, enhancing insulin secretion, suppressing glucagon release, and delaying gastric emptying, making them effective in addressing hyperglycemia while exhibiting favorable effects on other metabolic parameters [3, 4]. Their impact on blood pressure regulation represents a critical area of exploration, given the interconnected relational nature of diabetes, obesity, and hypertension.

In diabetes management, GLP-1 RAs have been transformative due to their ability to achieve robust reductions in glycated hemoglobin (HbA1c) levels without significantly increasing the risk of hypoglycemia [5, 6]. These agents facilitate glucose-dependent insulin secretion, providing more physiological glycemic control compared to traditional therapies. Beyond glucose lowering, GLP-1 RAs induce satiety and promote weight loss, addressing the obesity-diabetes nexus that exacerbates insulin resistance and complicates disease management [7, 8]. Importantly, GLP-1 RAs also demonstrate reno-protective properties. Clinical trials and mechanistic studies suggest they reduce intraglomerular pressure through natriuretic effects, lower albuminuria, and attenuate the progression of diabetic kidney disease by reducing renal oxidative stress and inflammation [9, 10]. The broad spectrum of benefits offered by GLP-1 RAs underscores their value as foundational therapies in the management of diabetes and its complications.

The antihypertensive effects of GLP-1 RAs are thought to be mediated by several mechanisms, including improved endothelial function, reduced arterial stiffness, and modulation of the autonomic nervous system to decrease sympathetic activity [11, 12]. These effects are complemented by significant weight loss, which itself contributes to reductions in systolic and diastolic blood pressures [13]. Additionally, GLP-1 RAs have been shown to attenuate oxidative stress and inflammatory pathways, further supporting vascular health [14, 15].

Clinical trials have demonstrated that GLP-1 RAs, such as liraglutide and semaglutide, reduce blood pressure across diverse populations with T2DM and obesity. However, variability in individual responses underscores the complexity of their effects and highlights the need to identify patient subgroups most likely to benefit from this therapy. Moreover, the durability and long-term implications of these blood pressure-lowering effects remain areas requiring further investigation. This review synthesizes peer-reviewed evidence available to date that elucidates the role of GLP-1 RAs in blood pressure regulation, and examines their mechanisms of action, clinical efficacy, and broader cardiovascular implications. By integrating findings from preclinical studies, randomized controlled trials, and meta-analyses, this review aims to provide a comprehensive understanding of the therapeutic potential of GLP-1 RAs in managing hypertension within the framework of diabetes and obesity care.

GLP-1 RAs decrease blood pressure through various direct and indirect mechanisms. These mechanisms include effects on the vasculature, neurohormonal modulation, renal physiology, and body weight, all of which contribute to reductions in systemic blood pressure (Fig. 1).

Fig. 1.

Mechanisms of GLP-1 receptor agonists in blood pressure reduction. GLP-1, glucagon-like peptide-1; BP, blood pressure; RAAS, renin-angiotensin-aldosterone system. Upward arrows ($\uparrow$) denote an increase or enhancement, while downward arrows ($\downarrow$) represent a decrease or suppression.

GLP-1 receptors are expressed at low levels in the heart and vasculature; still, activation of these receptors can induce beneficial vascular changes [16]. GLP-1 RAs have been shown to improve endothelial function and promote vasodilation, partly via nitric oxide (NO) dependent pathways. For instance, in studies of patients with diabetes, GLP-1 infusion or GLP-1 RA therapy enhanced endothelium-dependent vasodilation and increased NO release [17]. Basu et al. [18] observed that GLP-1 infusion improved acetylcholine-mediated vasorelaxation and even lowered diastolic blood pressure (BP) in type 1 diabetic patients. Additionally, GLP-1 RAs also exhibit anti-inflammatory and anti-atherosclerotic effects on the vasculature, which may further improve endothelial function [12, 19]. Notably, GLP-1 RAs tend not to significantly affect diastolic pressure in most patients, likely because their vasodilatory effect primarily impacts systolic pressure and large artery compliance.

GLP-1 RAs can also influence the autonomic nervous system, although the net impact on BP is complex. GLP-1 receptors in the brain may stimulate sympathetic outflow. Acute administration of native GLP-1 or GLP-1 RAs has been associated with increased heart rate, suggesting some degree of sympathetic activation [20, 21]. Preclinical studies indicate that GLP-1 in the paraventricular nucleus can raise blood pressure via sympathetic nervous activation. In clinical trials, GLP-1 RAs consistently produce a modest increase in heart rate of about 2–4 beats per minute [22]. This mild tachycardic effect is thought to be mediated by GLP-1 receptor activation in autonomic centers of the heart, and it occurs irrespective of the presence of hypertension. While increased heart rate is generally a counter-regulatory response that could blunt BP reduction, the overall blood pressure effect of GLP-1 RAs remains a net decrease, as other mechanisms such as vasodilation, natriuresis, and weight loss dominate. Some have raised concerns that chronic slight tachycardia might offset cardiovascular benefits, but the major outcome trials did not find a harmful impact of the heart rate increase. In summary, GLP-1 agonists likely engage sympathetic pathways, resulting in a small rise in heart rate but no adverse arrhythmic effect, while still allowing an overall blood pressure reduction through other means.

Another important mechanism by which GLP-1 RAs may lower blood pressure is through renal sodium and water excretion. GLP-1 receptors in the kidneys, specifically in the proximal tubule, can promote natriuresis and diuresis when activated. Studies have demonstrated that GLP-1 RA administration increases sodium excretion. For instance, Skov et al. [23] found that intravenous GLP-1 infusion in healthy men induced significant natriuresis and diuresis, accompanied by a reduction in plasma angiotensin II levels. This suggests GLP-1 signaling can downregulate the renin-angiotensin-aldosterone system (RAAS). Clinically, GLP-1 RAs have demonstrated direct natriuretic effects. A study in patients with type 2 diabetes showed that liraglutide acutely increased urinary sodium excretion despite no change in atrial natriuretic peptide levels, confirming a natriuretic action in humans [24]. By promoting sodium loss and possibly antagonizing RAAS, GLP-1 RAs reduce plasma volume and vascular resistance, contributing to lower blood pressure. Overall, the evidence strongly suggests GLP-1 receptor activation helps control blood pressure at least partly by improving renal sodium handling and reducing RAAS activity [12].

GLP-1 RAs are potent weight-reducing agents, and weight loss is a well-known strategy to lower blood pressure in overweight individuals. Reductions in adiposity lead to improved insulin sensitivity, decreased circulating insulin (hyperinsulinemia can raise BP by renal sodium retention), reduced inflammatory cytokines, and improved vascular function; all of which can lower blood pressure. On average, GLP-1 RA therapy produces significant weight loss over months; this likely mediates a portion of the blood pressure reduction. In fact, meta-regression analyses have found that the extent of BP lowering with GLP-1 RAs correlates with the magnitude of weight loss. A recent meta-analysis by Rivera et al. [25] noted that patients on GLP-1 RAs experienced modest systolic BP reductions in parallel with reductions in body mass index (BMI) and hemoglobin A1c, suggesting the BP effect is secondary to improvements in weight and metabolic control. Weight loss of 5–10% is known to significantly improve BP in hypertensive patients, as evidenced by lifestyle intervention studies [26]. Therefore, the substantial weight reduction induced by GLP-1 RAs is a key indirect mechanism for lowering BP. Importantly, GLP-1 RAs reduce blood pressure even before dramatic weight loss occurs, indicating other direct effects are also at play early in therapy [27]. But over the longer term, decreased adiposity, improved insulin sensitivity, and lower sympathetic drive from weight loss all contribute to sustained blood pressure improvements.

Large clinical trials have provided critical insights into the cardiovascular benefits of GLP-1 RAs, particularly their impact on blood pressure regulation. The results of these studies are summarized in Table 1 (Ref. [28, 29, 30, 31]).

Given the modest blood pressure reductions with GLP-1 RAs, a natural question is how they compare to conventional antihypertensive drugs. In general, the BP-lowering effect of GLP-1 RAs is less than that of standard antihypertensive medications when used in monotherapy. Most first-line antihypertensive drug classes such as ACE inhibitors, angiotensin receptor blockers, thiazide diuretics, and calcium channel blockers lower systolic BP by roughly 5–15 mmHg on average in hypertensive patients, depending on baseline BP and dose [32, 33, 34, 35]. Even newer agents like SGLT2 inhibitors typically lower SBP ~4–5 mmHg [36, 37, 38, 39]. Thus, GLP-1 RAs should not be viewed as replacements for dedicated BP medications when significant BP lowering is required. However, GLP-1 RAs can provide an additive BP-lowering effect when used alongside conventional antihypertensives.

When considering efficacy, GLP-1 RAs alone are generally insufficient for treating moderate or severe hypertension, but they can meaningfully improve BP in patients whose levels are just above goal despite standard therapy. An interesting comparison is with weight-loss medications, in a network meta-analysis of weight management trials in overweight hypertensives, GLP-1-based agents were associated with the largest BP reductions among pharmacotherapies [40]. Tirzepatide led the pack with ~6.5 mmHg SBP and ~3.6 mmHg DBP lowering vs placebo, outperforming older weight-loss drugs like orlistat or phentermine-topiramate which lowered SBP by ~2–4 mmHg [40]. This underscores that for an obese hypertensive patient, a GLP-1 RA can provide an antihypertensive benefit comparable to adding a mild BP drug, especially as part of a weight-centric strategy.

Beyond efficacy, the tolerability and suitability of GLP-1 RAs differ substantially from traditional antihypertensive agents. GLP-1 RAs are associated with gastrointestinal side effects such as nausea, vomiting and diarrhea most prominent during initiation and dose titration. These adverse events along with their higher cost can limit long-term adherence and make them less practical for patients who do not also have diabetes or obesity. By contrast, conventional antihypertensives have long-established safety profiles in diverse populations with hypertension. However, they do not confer metabolic or weight-reducing benefits. This highlights that patient selection is crucial. GLP-1 RAs are especially valuable for obese or diabetic hypertensive patients.

The most significant advantage of utilizing GLP-1 RAs is their metabolic benefits along with the modest BP reductions. The significant weight loss, improved glycemic control, favorable impact on lipid profile, reduction in inflammation and improved endothelial function make it a wonderful choice of lowering cardiovascular risk. No traditional anti-hypertensive offers this wide range of benefits. Therefore, as an adjunct, GLP-1 RAs can be particularly beneficial in patients with both hypertension and diabetes and/or obesity.

There are, of course, no indications or recommendations for GLP-1 RA use solely for hypertension control as important limitations to using them for blood pressure management exist. First, they are less potent at lowering BP than dedicated antihypertensive drugs, as noted. A patient with significantly elevated BP will still require standard antihypertensive therapy; a GLP-1 RA would be insufficient as monotherapy to reach BP targets in most cases. Second, GLP-1 RAs are costly, which makes them impractical to use solely for mild BP elevation if the patient has no other indication. Third, side effects of GLP-1 RAs need to be considered with the most common ones being gastrointestinal (nausea, vomiting, diarrhea), especially during initiation and titration.

Current guidelines underscore this adjunctive role. The American Diabetes Association recommends GLP-1 RAs with proven cardiovascular benefit such as liraglutide, semaglutide or dulaglutide for patients with type 2 diabetes and established atherosclerotic cardiovascular disease or high cardiovascular risk irrespective of HbA1c level or background therapy. Similarly, the 2023 European Society of Hypertension guidelines acknowledge the favorable metabolic and weight-loss effects of GLP-1 RAs but do not endorse them as first-line antihypertensive drugs. These recommendations reinforce the concept that GLP-1 RAs should complement not replace the conventional antihypertensives when cardiovascular risk reduction is the therapeutic priority.

In summary, GLP-1 RAs complement but do not replace traditional antihypertensive therapy. Their modest BP reduction can be thought of as equivalent to adding a mild antihypertensive. The real value of GLP-1 RAs lies in their multi-factorial benefits. For the growing population of patients with the co-morbid conditions of hypertension, diabetes, and obesity, GLP-1 RAs represent an opportunity to simultaneously treat multiple risk factors with one agent.

DG, FB and AM designed the research study, performed the research, collected the data and wrote the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Not applicable.

This research received no external funding.

The authors declare no conflict of interest.